MGCD265 - Met Inhibitor / Anti-Angiogenesis

[Fictional]

FYI. Don't know anything about this drug.

Two recruiting clinical trials: http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=1
and http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=2

Sites are Vancouver, Duke, and Dana Farber
Second is at Detroit / Karmanos and Texas

Comes from Methygene and open label Phase I.

Targets c-met, Tie-2, RON, and 3 VEGF receptor tyrosine kinases (RTKs).

XL880 is another attempt at met inhibitor + antiangiogenesis, but we have heard that it is a relatively weak met inhibitor, and one ASPS patient that we know of with disseminated disease did not benefit.